Results 51 to 60 of about 30,070 (260)

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Frontiers in Oncology, 2021
The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms.
Andrea Kuendgen, Annika Kasprzak, Ulrich Germing   +2 more
doaj   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

Animal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam, Aashika Raagavi Jeanpierre, Salma Mohammed, Rajesh Srinivasan, Aman Kumar Mohanty   +4 more
wiley   +1 more source

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm

Data in Brief, 2023
Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis.
Umi Kalsom Mohamad Yusof, Syamsiah Mashohor, Marsyita Hanafi, Sabariah Md Noor, Norsafina Zainal   +4 more
doaj   +1 more source

Myeloproliferative neoplasms and thrombosis

Blood, 2013
Abstract Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors.
Barbui, Tiziano, Finazzi, Guido, Falanga, Anna   +2 more
openaire   +3 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm

, 2010
Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm (MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2, remain obscure.
Chen, Edwin, Kusec, Rajko, McMullin, Mary Frances, Harrison, Claire N, Beer, P.A., Vainchenker, W., Delhommeau, François, Lecouedic, J.P., Dawson, Mark A, Delhommeau, F., Vannucchi, A., Kusec, R., McMullin, M.F., Vainchenker, William, Vannucchi, Alessandro M, Beer, Philip A, Chen, E., Bareford, D., LeCouédic, Jean-Pierre, Bareford, David, Harrison, C.N., Green, A.R., Green, Anthony R, Dawson, M.A.   +23 more
core   +1 more source

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi, Dorothée Selimoglu‐Buet, Ivan Sloma, Orianne Wagner‐Ballon, on behalf of the French group CytHem‐LMMC   +4 more
wiley   +1 more source

Myeloproliferative neoplasms in children [PDF]

Journal of Hematopathology, 2015
Myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic stem cell disorders characterized by aberrant proliferation of one or more myeloid lineages often with increased immature cells in the peripheral blood. The three classical BCR-ABL-negative MPNs are: 1) polycythemia vera (PV), 2) essential thrombocythemia (ET), and 3) primary ...
openaire   +2 more sources

From Basics to Benchmarks: Evaluating Sample Adequacy, PD‐L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Omid Savari, Aparna Harbhajanka   +5 more
wiley   +1 more source

Myeloproliferative Neoplasms: An Overview [PDF]

American Society for Clinical Laboratory Science, 2011
1. Kathleen Finnegan, MS, MT(ASCP)SHCM[⇑][1] 1. Stony Brook University Health Science Center, School of Health Technology and Management, Stony Brook, NY 1. Address for Correspondence: Kathleen Finnegan, MS, MT(ASCP)SHCM, Chair, Department of Clinical Laboratory Sciences, Stony Brook University Health Science Center, School of Health ...
openaire   +2 more sources